Immunotherapy is an important new FDA approved treatment approach that has become part of the standard of care for endometrial cancers [74,75], and p53 reactivators have the potential to further enhance immunotherapy in the treatment of endometrial cancer. The gene discussed is TP53; the disease is endometrial cancer.